León-Román Juan, López-Martínez Marina, Esteves Alexandra, Ciudin Andreea, Núñez-Delgado Sara, Álvarez Tiffany, Lecube Albert, Rico-Fontalvo Jorge, Soler María José
Nephrology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Research, CSUR National Unit of Expertise for Complex Glomerular Diseases of Spain, Paseo de la Vall d´Hebron 119, 08035 Barcelona, Spain.
Department of Medicine, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
Int J Mol Sci. 2025 Jul 10;26(14):6641. doi: 10.3390/ijms26146641.
Obesity represents a serious and growing disease worldwide. The pathophysiological changes secondary to chronic inflammation lead to the development of diseases that increase the morbidity and mortality of individuals. Chronic kidney disease (CKD) is a condition with deleterious effects that acts bidirectionally with obesity. From approximately 20% to 30% of individuals share phenotypes of CKD and obesity, increasing their cardiovascular risk and the risk of other complications. Obesity and CKD form a vicious cycle in which inflammation is the central axis of multiorgan damage. Despite increasing the risk of cardiac and renal mortality, CKD progresses in relation to body mass index and albuminuria. Nowadays, the implementation of the new medications aimed at mitigating the peak of inflammation is becoming a cornerstone of treatments for obesity, diabetes, cardiovascular diseases, and renal disease.
肥胖是一种在全球范围内严重且日益普遍的疾病。继发于慢性炎症的病理生理变化会导致疾病的发生,进而增加个体的发病率和死亡率。慢性肾脏病(CKD)是一种具有有害影响的疾病,与肥胖存在双向作用。大约20%至30%的个体同时具有CKD和肥胖的表型,这增加了他们的心血管疾病风险以及其他并发症的风险。肥胖和CKD形成了一个恶性循环,其中炎症是多器官损伤的核心环节。尽管CKD会增加心脏和肾脏死亡风险,但它的进展与体重指数和蛋白尿有关。如今,使用旨在减轻炎症高峰的新型药物正成为肥胖、糖尿病、心血管疾病和肾脏疾病治疗的基石。